In a recent analysis of HRSA data, the American Hospital Association has turned the tables on drug companies and accused them of being far more likely to violate 340B Drug Pricing Program rules.
In the heated debate over the 340B Drug Pricing Program, hospitals have frequently been forced to play defense, facing frequent accusations of program abuse from drug companies and occasionally from lawmakers. While drug companies have consistently called for strict oversight of providers and changes to program rules, a recent analysis from the American Hospital Association suggests that drug companies are far less likely to play by the rules.
Check out the infographic below for key insights from the report, or read more here.
Luke Gale is the revenue cycle editor for HealthLeaders.
KEY TAKEAWAYS
An analysis of HRSA data conducted by the American Hospital Association (AHA) suggests that drug companies are more likely to violate 340 Drug Pricing Program rules than hospitals.
A significantly smaller share of participating drug companies are subjected to audits than participating hospitals.
Based on the findings, AHA has called for increased oversight of participating drug companies to ensure the program's integrity.